Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VINC |
---|---|---|
09:32 ET | 40112 | 0.809999 |
09:34 ET | 17499 | 0.805 |
09:36 ET | 30592 | 0.8001 |
09:38 ET | 7914 | 0.7902 |
09:39 ET | 40823 | 0.7651 |
09:41 ET | 6762 | 0.7607 |
09:43 ET | 1400 | 0.7607 |
09:45 ET | 4643 | 0.77 |
09:48 ET | 14871 | 0.7611 |
09:50 ET | 900 | 0.77 |
09:52 ET | 5068 | 0.7749 |
09:54 ET | 4400 | 0.7934 |
09:56 ET | 1600 | 0.79 |
09:57 ET | 2929 | 0.790101 |
09:59 ET | 450 | 0.7934 |
10:01 ET | 2040 | 0.7901 |
10:03 ET | 120 | 0.789244 |
10:06 ET | 2000 | 0.7801 |
10:08 ET | 9395 | 0.7868 |
10:10 ET | 13830 | 0.7917 |
10:12 ET | 10000 | 0.785 |
10:14 ET | 4876 | 0.7988 |
10:15 ET | 14216 | 0.8025 |
10:17 ET | 400 | 0.8025 |
10:19 ET | 9697 | 0.813 |
10:21 ET | 14873 | 0.8204 |
10:24 ET | 6850 | 0.825999 |
10:26 ET | 6469 | 0.8258 |
10:28 ET | 11600 | 0.8258 |
10:32 ET | 549 | 0.8258 |
10:33 ET | 3200 | 0.8201 |
10:35 ET | 400 | 0.82 |
10:37 ET | 7000 | 0.82 |
10:39 ET | 6177 | 0.82 |
10:42 ET | 2401 | 0.82 |
10:44 ET | 13580 | 0.82 |
10:46 ET | 34973 | 0.818 |
10:48 ET | 20800 | 0.817 |
10:50 ET | 6959 | 0.8207 |
10:51 ET | 3700 | 0.8207 |
10:53 ET | 438 | 0.818 |
10:55 ET | 7111 | 0.8105 |
10:57 ET | 6143 | 0.8046 |
11:00 ET | 3196 | 0.80955 |
11:02 ET | 300 | 0.80955 |
11:04 ET | 1000 | 0.801 |
11:06 ET | 2800 | 0.8078 |
11:08 ET | 1895 | 0.8144 |
11:09 ET | 600 | 0.8077 |
11:11 ET | 100 | 0.8101 |
11:13 ET | 1500 | 0.8101 |
11:18 ET | 14184 | 0.7901 |
11:20 ET | 2329 | 0.810101 |
11:22 ET | 200 | 0.8102 |
11:24 ET | 500 | 0.8112 |
11:26 ET | 900 | 0.815 |
11:27 ET | 100 | 0.81255 |
11:29 ET | 200 | 0.81115 |
11:31 ET | 1000 | 0.8102 |
11:33 ET | 4037 | 0.8101 |
11:36 ET | 3800 | 0.81015 |
11:38 ET | 100 | 0.81015 |
11:40 ET | 100 | 0.8102 |
11:42 ET | 7791 | 0.81015 |
11:44 ET | 7219 | 0.80515 |
11:45 ET | 3300 | 0.81 |
11:47 ET | 200 | 0.80775 |
11:49 ET | 300 | 0.80905 |
11:54 ET | 10676 | 0.81725 |
11:56 ET | 32289 | 0.8123 |
11:58 ET | 1900 | 0.81235 |
12:00 ET | 200 | 0.81005 |
12:02 ET | 2315 | 0.81005 |
12:03 ET | 2489 | 0.8101 |
12:05 ET | 676 | 0.81295 |
12:07 ET | 5100 | 0.81114 |
12:09 ET | 9154 | 0.8102 |
12:12 ET | 400 | 0.81835 |
12:14 ET | 1100 | 0.81535 |
12:16 ET | 12900 | 0.81275 |
12:18 ET | 2900 | 0.8154 |
12:20 ET | 1300 | 0.81415 |
12:21 ET | 9560 | 0.8141 |
12:23 ET | 2900 | 0.8179 |
12:25 ET | 100 | 0.8179 |
12:27 ET | 2800 | 0.8216 |
12:30 ET | 1800 | 0.821 |
12:32 ET | 26300 | 0.8351 |
12:34 ET | 14220 | 0.8305 |
12:36 ET | 23330 | 0.8435 |
12:38 ET | 3196 | 0.8305 |
12:39 ET | 2910 | 0.821 |
12:41 ET | 2396 | 0.825901 |
12:43 ET | 1300 | 0.83 |
12:45 ET | 8900 | 0.8111 |
12:48 ET | 414 | 0.811 |
12:50 ET | 6592 | 0.81 |
12:52 ET | 12639 | 0.81 |
12:54 ET | 3487 | 0.8101 |
12:56 ET | 4095 | 0.81 |
12:57 ET | 3457 | 0.81 |
12:59 ET | 3000 | 0.81 |
01:01 ET | 4997 | 0.811225 |
01:03 ET | 3426 | 0.8 |
01:06 ET | 4611 | 0.805 |
01:08 ET | 3600 | 0.8049 |
01:10 ET | 7100 | 0.805 |
01:12 ET | 10300 | 0.8112 |
01:14 ET | 1300 | 0.8224 |
01:15 ET | 1000 | 0.8162 |
01:17 ET | 202 | 0.8101 |
01:19 ET | 200 | 0.8101 |
01:21 ET | 101 | 0.8102 |
01:24 ET | 100 | 0.8163 |
01:26 ET | 1700 | 0.8101 |
01:28 ET | 8601 | 0.8102 |
01:30 ET | 1000 | 0.8101 |
01:39 ET | 500 | 0.8162 |
01:42 ET | 524 | 0.8162 |
01:44 ET | 1000 | 0.815 |
01:46 ET | 100 | 0.815 |
01:48 ET | 100 | 0.8101 |
01:50 ET | 100 | 0.815 |
01:53 ET | 2800 | 0.8224 |
01:55 ET | 1500 | 0.81051 |
01:57 ET | 500 | 0.81645 |
02:00 ET | 900 | 0.8174 |
02:02 ET | 300 | 0.8145 |
02:04 ET | 3535 | 0.8165 |
02:06 ET | 100 | 0.8222 |
02:08 ET | 1300 | 0.8165 |
02:09 ET | 3512 | 0.8125 |
02:11 ET | 1600 | 0.8124 |
02:13 ET | 3100 | 0.8124 |
02:15 ET | 5777 | 0.8025 |
02:18 ET | 3500 | 0.8025 |
02:20 ET | 5734 | 0.8026 |
02:22 ET | 4405 | 0.7984 |
02:24 ET | 23178 | 0.7866 |
02:26 ET | 5999 | 0.7801 |
02:27 ET | 9472 | 0.7969 |
02:29 ET | 600 | 0.793 |
02:31 ET | 4600 | 0.793 |
02:33 ET | 4600 | 0.793 |
02:36 ET | 6450 | 0.7926 |
02:38 ET | 8867 | 0.7813 |
02:40 ET | 9148 | 0.78 |
02:42 ET | 5955 | 0.781 |
02:44 ET | 5797 | 0.781 |
02:45 ET | 10470 | 0.789799 |
02:47 ET | 5156 | 0.77 |
02:49 ET | 2600 | 0.7773 |
02:51 ET | 300 | 0.7701 |
02:54 ET | 2185 | 0.77 |
02:56 ET | 8977 | 0.7753 |
02:58 ET | 1000 | 0.77 |
03:00 ET | 700 | 0.77 |
03:02 ET | 1121 | 0.77 |
03:03 ET | 101 | 0.7701 |
03:05 ET | 4500 | 0.77 |
03:07 ET | 2200 | 0.775 |
03:09 ET | 22400 | 0.7868 |
03:12 ET | 9300 | 0.8 |
03:14 ET | 200 | 0.7875 |
03:16 ET | 9808 | 0.7867 |
03:18 ET | 7700 | 0.76975 |
03:20 ET | 11800 | 0.7693 |
03:21 ET | 5300 | 0.7693 |
03:23 ET | 14328 | 0.7782 |
03:25 ET | 6970 | 0.7726 |
03:27 ET | 21045 | 0.7601 |
03:30 ET | 5399 | 0.76 |
03:32 ET | 13017 | 0.76 |
03:34 ET | 8500 | 0.76 |
03:36 ET | 14500 | 0.76 |
03:38 ET | 20121 | 0.7651 |
03:39 ET | 6189 | 0.75 |
03:41 ET | 13000 | 0.75 |
03:43 ET | 21400 | 0.7598 |
03:45 ET | 16097 | 0.7691 |
03:48 ET | 15247 | 0.75 |
03:50 ET | 18696 | 0.75 |
03:52 ET | 33121 | 0.76455 |
03:54 ET | 23452 | 0.7563 |
03:56 ET | 25242 | 0.7589 |
03:57 ET | 45608 | 0.74985 |
03:59 ET | 174950 | 0.73 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vincerx Pharma Inc | 19.2M | -0.4x | --- |
Raphael Pharmaceutical Inc | 18.7M | -12.5x | --- |
Indaptus Therapeutics Inc | 18.6M | -1.1x | --- |
CytoMed Therapeutics Ltd | 25.4M | -5.4x | --- |
Alaunos Therapeutics Inc | 18.6M | -0.6x | --- |
Biomx Inc | 18.6M | -0.6x | --- |
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $19.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.17 |
EPS | $-1.89 |
Book Value | $0.52 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.